Glutenase

Glutenase: A Comprehensive Reference

1. Identity and Nomenclature

Glutenase is a collective functional term — not a single chemical entity — applied to any enzyme or enzyme preparation capable of degrading gluten proteins and, specifically, their immunogenic peptide fragments. These novel enzymes, termed "glutenases," are devised as oral supplements supporting the gluten-free diet (GFD) and protecting from unintentional gluten exposures. The term therefore encompasses several structurally and biochemically distinct protease types from bacterial, fungal, plant, and cereal sources, united by a shared functional objective: the proteolytic detoxification of gliadin and related prolamin proteins in the gastrointestinal tract.

The principal enzyme classes that have been studied or marketed under this umbrella include:

• Prolyl endopeptidases (PEPs) / Prolyl endoproteases: Serine or cysteine proteases that cleave peptide bonds on the carboxyl side of internal proline residues. Prolyl endopeptidases (PEP) hydrolyse internal proline residues on the carboxyl side of peptides and have been proposed for food gluten detoxification and as oral enzyme supplementation for celiacs.
• AN-PEP (Aspergillus niger Prolyl Endoprotease): Also commercially known as Tolerase G (DSM Nutritional Products). Extracellular prolyl endoprotease (AN-PEP), derived from Aspergillus niger, was first created for the purpose of debittering protein hydrolysates.
• DPP-IV (Dipeptidyl Peptidase IV; EC 3.4.14.5): An X-Pro N-terminal exopeptidase. Some digestive supplements contain dipeptidyl peptidase IV (DPP-IV), an X-Pro amino-exopeptidase from Aspergillus oryzae, inactive at stomach pH 3.5, but optimally active at intestinal pH 7.0.
• Caricain (EC 3.4.22.30): A cysteine protease derived from the latex of Carica papaya. Caricain (EC 3.4.22.30) from papaya latex is a component of the most active commercially studied supplement (GluteGuard). The enzyme was first described by Schack.
• EP-B2 (Endoprotease B, Isoform 2): A glutamine-specific cysteine endoprotease derived from barley (Hordeum vulgare). It is secreted naturally in the acidic endosperm of germinating barley seeds (Hordeum vulgare) where it serves to digest hordein, the analog of gliadin.
• ALV003 / Latiglutenase: A combination investigational drug. Latiglutenase (ALV003) is an experimental oral drug comprising two recombinant proteases: ALV001 and ALV002. ALV001 is a cysteine endoprotease B-isoform, while ALV002 is a prolyl endopeptidase.

2. Natural Sources and Common Forms/Preparations

Endopeptidases produced by various plants, bacteria, or fungi have been studied and demonstrated to degrade at different extents the proline/glutamine-rich gluten peptides in the gastric and upper intestinal tracts, thus "detoxifying" gluten. The natural biological sources for the principal glutenases studied in the literature are as follows:

• Aspergillus niger (black mold fungus): Source of AN-PEP, which was originally developed for debittering protein hydrolysates. In the brewing industry, this enzyme is mainly applied for the prevention of haze formation.
• Aspergillus oryzae (koji mold): Source of food-grade DPP-IV used in most commercial supplement products.
• Carica papaya (papaya): Papaya latex is a source of enzymes used in the food industry and medicine. Crude extract has long been known to digest wheat proteins ex vivo, and reduce wheat immunogenicity in susceptible patients. It contains the proteases papain, chymopapain, and glutamine cyclotransferase, as well as the cysteine protease caricain [EC 3.4.22.30, also known as papaya proteinase omega], which in prior clinical studies has been shown to eliminate the immune reactive proteins leading to a decreased level of immune response.
• Hordeum vulgare (barley): Source of EP-B2. It is secreted naturally in the acidic endosperm of germinating barley seeds (Hordeum vulgare) where it serves to digest hordein, the analog of gliadin. Glutenase EP-B2 is optimally active at low pH, resistant to pepsin but lysed at physiological concentrations of trypsin, and has good specificity for the sequence QXP, which is abundant in the 33-mer as well as other immunotoxic gluten sequences.
• Microbial sources (bacteria): Endopeptidase 40 (E40), a novel glutenase, was discovered as secreted protein from the soil actinomycete Actinoallomurus A8, with a recombinant active form produced by Streptomyces lividans TK24. Additionally, a bacterial isolate (2RA3) showing the highest glutenase activity was identified through 16S rDNA gene sequencing with 99.1% similarity to Chryseobacterium taeanense.
• Sphingomonas capsulata: ALV003 is manufactured as a mixture of cysteine protease obtained from barley and PEP from Sphingomonas capsulata. It is capable of degrading immunogenic gluten fragments in the stomach.

Common commercial preparations of glutenase supplements are predominantly formulated as oral capsules or tablets, taken with meals. Among 14 glutenase products surveyed, all contained proteases; eight contained the X-prolyl exopeptidase DPP-IV, two did not state protease contents, and eight failed to specify the name or origin of all proteases. Eleven contained carbohydrases and lipases, and three contained probiotics. Some preparations, such as GluteGuard, use enteric coating to target enzyme delivery to the stomach. Each tablet of GluteGuard contained 18,000 units (U) of caricain, a natural enzyme derived from papaya fruit (Carica papaya).

3. Traditional and Historical Use

The term "glutenase" is a modern scientific coinage and does not correspond to any single traditional herbal or dietary preparation. However, the plant sources from which certain glutenase enzymes are derived do have documented pre-scientific histories of use.

Papaya (Carica papaya): The use of papaya latex and unripe papaya fruit as a digestive aid has a long record in traditional medicine across tropical regions of Central and South America, Africa, and South and Southeast Asia, where the plant is native and widely cultivated. The crude latex was historically applied topically for wound healing and ingested to facilitate protein digestion. The broader proteolytic activity of crude papaya latex — including that of papain, chymopapain, and caricain — has been recognized in food science for more than a century, where it has been used in meat tenderization and the clarification of beverages. Papaya latex is a source of enzymes used in the food industry and medicine. The specific identification of caricain as a distinct enzyme with anti-gluten properties is, however, a development of modern biochemistry.

Barley (Hordeum vulgare): Barley has been a staple grain in agriculture for thousands of years, and germinated barley (malt) has been central to brewing traditions worldwide. Apart from microbial enzymes, a range of endogenous seed proteases in cereals are known to destroy immunotoxic gluten epitopes. Germination provides the necessary hydrolytic enzymes to modify the grain and degrade storage proteins such as hordeins. While these naturally occurring hydrolytic activities were not exploited specifically for anti-celiac purposes in historical traditions, the enzymatic activity of malted grains in modifying protein structure is an empirically observed phenomenon of long standing in brewing.

The deliberate isolation and formulation of specific proteolytic enzymes as "glutenases" — intended to mitigate harm from gluten ingestion — is entirely a product of late 20th and early 21st century biochemical and clinical research, with no documented parallel in pre-modern therapeutic systems.

4. The Gluten Problem: Biochemical Context

To understand why glutenases exist and what they are meant to do, the biochemistry of gluten must be understood. Gluten is a complex of proteins present in barley, wheat, rye, and several varieties of oats that triggers celiac disease in genetically predisposed subjects. Gluten is notoriously difficult to digest by mammalian proteolytic enzymes, and therefore proline-rich digestion-resistant peptides contain multiple immunogenic epitopes.

Gluten contains high amounts of the amino acid proline. Human gastrointestinal proteases do not accept proline at their cleavage sites, which is why gluten proteins remain largely undigested. The immunogenicity of gluten in wheat can mostly be attributed to epitopes in α-, γ-, and ω-gliadin fragments. This incomplete digestion results in the persistence of long proline- and glutamine-rich peptides — most notably the immunodominant "33-mer" α-2 gliadin peptide — in the intestinal lumen. Mammalian enzymes cannot effectively break down proline and glutamine-rich protein sequences, resulting in incomplete degradation of gluten in the intestinal lumen. This exposes the intestinal mucosa to immunogenic gluten peptides, which in celiac disease (CeD) will reactivate the disease and gluten-specific T cells.

The mode of action of these enzymes is based on studies that have shown that the immunogenicity of gluten can be reduced by breaking down the gluten protein into smaller peptides.

5. Key Constituents and Active Compounds

5.1 AN-PEP (Aspergillus niger Prolyl Endoprotease)

AN-PEP is active between a pH of 2 and 8, with optimal activity between pH 4 and 5. It is not degraded by pepsin, thereby remaining fully functional in the stomach. It specifically degrades gluten epitopes by cleaving behind proline residues. AN-PEP successfully cleaves those epitopes into smaller, non-immunogenic peptides of eight amino acids or smaller.

5.2 DPP-IV (Dipeptidyl Peptidase IV)

Most commercial glutenase products contain the fungal enzyme DPP-IV, a dipeptidyl peptidase. DPP-IV has its pH optimum at a neutral pH, suggesting that it might not be very effective in the low pH environment of the stomach. In addition, DPP-IV only releases proline-containing dipeptides from the N-terminus and has no endoprotease activity, so that larger polypeptide remnants may still contain immunogenic activity.

5.3 Caricain (EC 3.4.22.30)

Caricain cleaves the C-terminus of proline residues. Caricain cleaves purified gliadin and gliadin in whole wheat flour and detoxified gliadin extracts. In a gastric-like milieu, it exhibits relative resistance to pepsin cleavage, as well as optimal activity at a pH of 3.0/37°C. Upon incubation with gluten, it causes the cleavage of α, γ, ω, and glutenin fractions. However, in the presence of trypsin/pH 8.0/37°C, the enzyme is susceptible to destruction. Hence it may be effective only in the gastric digestion of wheat gluten prior to the food bolus reaching the intestine. The enzyme caricain (EC 3.4.22.30) is reported to have broad specificity for peptide bonds like papain (EC 3.4.22.2) and chymopapain (EC 3.4.22.6).

5.4 EP-B2 (Barley Endoprotease B, Isoform 2)

The glutenase EP-B2 (endoprotease B, isoform 2) is a glutamine-specific peptidase. Being a cysteine protease enzyme, it has a Cys-His-Asn catalytic triad in its active site. Celiac sprue is an inflammatory disease of the small intestine triggered by ingestion of dietary gluten, a family of glutamine- and proline-rich proteins found in common food grains such as wheat, rye, and barley. One potential therapy for this lifelong disease anticipates using an oral protease to detoxify gluten in vivo. Recent studies have shown that EP-B2 (endoprotease B, isoform 2) from barley is a promising example of such a glutenase, thus warranting its large-scale production for animal safety and human clinical studies.

5.5 ALV003 / Latiglutenase Components

Latiglutenase (ALV003) is an experimental oral drug comprising two recombinant proteases: ALV001 and ALV002. ALV001 is a cysteine endoprotease B-isoform, while ALV002 is a prolyl endopeptidase. These enzymes work synergistically to break down immunogenic gluten peptides. Its mechanism involves the sequential action of its enzymes: ALV001 targets specific sequences in the 31–43 and 33-mer peptides, breaking them into smaller fragments, while ALV002 cleaves proline-glutamine bonds, rendering the peptides non-immunogenic.

5.6 Novel Microbial Glutenases (Preclinical)

E40 (Endopeptidase 40) from Actinoallomurus is resistant to pepsin and trypsin, and active in the acidic pH range 3 to 6. E40 efficiently degrades the most immunogenic 33-mer as well as the whole gliadin proteins. The PEP enzyme from Chryseobacterium taeanense exhibits specificities of interest when targeting immunogenic gluten domains.

6. Scientific Evidence by Area of Use

6.1 Celiac Disease (CeD): Mucosal Protection

The best-evidenced glutenase in terms of clinical trials for celiac disease is ALV003 (Latiglutenase). Researchers investigated the ability of ALV003, a mixture of two recombinant gluten-specific proteases given orally, to protect patients with celiac disease from gluten-induced mucosal injury in a phase 2 trial. Adults with biopsy-proven celiac disease were randomly assigned to ALV003 (n=20) or placebo (n=21) together with a daily gluten challenge. Duodenal biopsies were collected at baseline and after the gluten challenge. Based on this phase 2 trial, the glutenase ALV003 appears to attenuate gluten-induced small intestinal mucosal injury in patients with celiac disease in the context of an everyday gluten-free diet containing daily up to 2 g gluten.

An earlier phase 1 study evaluated safety and activity. ALV003 is a mixture of two proteases that degrades gluten and was in clinical development as an oral therapy for patients with celiac disease. The safety, tolerability, and activity of ALV003 were assessed in two phase 1 clinical trials. In study 1 (N=28) the study drug was administered in the fasted state; in study 2 (N=53) the study drug was administered together with a gluten-containing meal. Both studies were single-dose, single-blind, placebo-controlled, cross-over trials. ALV003 was dosed at escalating dose levels by cohort (100, 300, 900, and 1,800 mg).

ALV003 has demonstrated safety in clinical studies, with no significant adverse reactions reported, even at doses as high as 1800 mg. Patients also showed improvements in symptoms and quality of life. Research indicates that Latiglutenase protects the intestinal mucosa, reduces gluten immunogenic peptide (GIP) levels in urine, and alleviates symptoms.

An earlier, smaller in vivo immunological challenge study examined immune response: Twenty patients with celiac disease were randomly assigned to ingest a large gluten meal (16 g daily for 3 days) pre-treated with ALV003 (n=10) or placebo (n=10). A significant ELISpot response to gliadin or the 33-mer was observed in 6 of 10 patients consuming placebo-treated gluten and 0 of 10 consuming ALV003 pre-treated gluten (p=0.011). Symptoms typically associated with gluten ingestion occurred in both groups and were not significantly reduced by ALV003 pre-treatment.

A published review characterized the overall evidence as showing double-blind, placebo-controlled clinical trials focused on ALV003 showing significant but limited benefit to celiac disease patients already compliant with a gluten-free diet. Other studies addressing other immune mechanisms that may play a role in pathogenesis have not been so positive. Additional investigations, particularly over the long-term, in other larger and more heterogeneous populations are needed.

6.2 Gluten Degradation in the Stomach: AN-PEP Clinical Evidence

AN-PEP has been assessed in human studies for its ability to degrade gluten within the stomach before it reaches the duodenum. In a randomised, double-blind, placebo-controlled, cross-over study, 12 healthy volunteers attended four test days. A liquid low or high calorie meal (4 g gluten) with AN-PEP or placebo was administered into the stomach. AN-PEP significantly enhanced gluten digestion in the stomach of healthy volunteers. Increasing caloric density prolonged gastric residence time of the meal. Since AN-PEP already degraded most gluten from low calorie meals, no incremental effect was observed by increasing meal caloric density.

A subsequent study examined AN-PEP in a more physiological, real-meal context. In a randomized placebo-controlled crossover study, 18 gluten-sensitive subjects consumed a porridge containing 0.5 g gluten together with two tablets either containing a high or low dose of AN-PEP, or placebo. Gastric and duodenal content was sampled over 180 minutes, and areas under the curve of gluten concentrations were calculated. In the duodenum, gluten levels were reduced from 14.1 (8.3–124.7) in the placebo to 6.3 (3.5–19.8, p=0.019) in the high dose and to 7.4 μg × min/ml in the low dose (3.8–12.0, p=0.015). Thus even in a physiological meal setting, AN-PEP significantly degraded most gluten in the stomach before it entered the duodenum.

Also using an in vitro gastrointestinal model: AN-PEP accelerated the degradation of gluten in the stomach compartment to such an extent that hardly any gluten reached the duodenum compartment.

Despite these findings, a critical review noted a key limitation: AN-PEP degrades gluten proteins under acid conditions in vitro and appeared to qualify as an oral supplement to reduce gluten exposure in patients. However, glutenases that are currently marketed as dietary supplements, including AN-PEP, have not been demonstrated to sufficiently degrade gluten in vivo and are therefore not to be recommended as a supplement.

6.3 Caricain (GluteGuard) in Celiac Disease and Dermatitis Herpetiformis

Clinical studies have shown that caricain supplements reduce gluten-induced symptoms. There are two key randomized, double-blind, placebo-controlled studies, firstly in patients with dermatitis herpetiformis and secondly in celiacs.

In the dermatitis herpetiformis study: Patients were challenged with 6 g of gluten daily for 14 days. Ten subjects received a placebo and 10 subjects received GluteGuard before each gluten challenge. Skin lesion size was significantly reduced by the treatment.

In the celiac disease study: A randomized placebo-controlled trial was carried out on 20 CD patients in clinical remission. The patients were divided into a group of 14 given GluteGuard and a group of 6 given placebo daily. Six patients were assigned to the placebo group and 14 to the caricain group who received GluteGuard. All subjects received 1 g of gluten daily for 45 days. Four of the placebo subjects abandoned the study due to severe symptoms. Treatment significantly protected against gluten-induced symptoms.

In this RCT, upon co-administration of caricain with 1 g gluten daily to 20 CeD patients in remission, patients had no worsening of symptom scores and histopathology. However, these trials had small sample sizes and were partly funded by the manufacturer, representing important limitations on the strength of the conclusions.

6.4 Non-Celiac Gluten Sensitivity (NCGS): Enzyme Combinations

One small clinical study assessed a combination enzyme supplement in NCGS. A single-blind crossover clinical trial was performed using a gluten challenge with an enzyme mixture or placebo. The enzyme mixture contained peptidase, semi-alkaline protease, deuterolysin, and cysteine protease derived from Aspergillus oryzae, Aspergillus melleus, Penicillium citrinum, and Carica papaya L., respectively. Administration of the enzyme mixture significantly decreased the change in the score of the symptom questionnaire before and after the gluten challenge compared with administration of the placebo in patients with NCGS without adverse events. In particular, the changes in the score of the gluten-induced incomplete evacuation feeling and headaches were significantly improved. This study is limited by its single-blind design and small patient population.

6.5 In Vitro Comparative Efficacy of Commercial Supplements

Endopeptidase-containing supplements may digest gluten and reduce the impact on celiac and gluten-sensitive subjects who inadvertently consume gluten. Researchers investigated the relative rate of disappearance of coeliac-relevant epitopes in extracts of nine commercial supplements, using two competitive ELISAs. All epitopes are destroyed by cleavage after P and Q amino acids. Rates at pH 3.5 and pH 7.0 were measured. These experiments were designed to measure relative rates of epitope digestion, not to mimic in vivo digestion. The supplements tested included GluteGuard, GlutenBlock, GliadinX, GlutnGo, GlutenRescue, Eat E-Z Gluten+, Glutenease, Glutezyme, and Gluten Digest. Results from prior clinical studies suggest that the caricain-containing supplement (GluteGuard) may be a useful adjunct to a gluten-free diet as a means of protecting those with CD and other gluten sensitivities from inadvertent dietary gluten contamination.

6.6 Barley EP-B2: Preclinical Animal Evidence

EP-B2 demonstrated in vivo ability as a gluten-digesting protease to accelerate the breakdown of a gluten-rich solid meal. The proenzyme form of endoprotease B, isoform 2 from Hordeum vulgare (EP-B2), was orally administered to adult rats with a solid meal containing 1 g of gluten. Gluten digestion in the stomach and small intestine was monitored as a function of enzyme dose and time by high-performance liquid chromatography and mass spectrometry. EP-B2 was remarkably effective at digesting gluten in the rat stomach in a dose- and time-dependent fashion. At a 1:25 EP-B2/gluten dose, the gastric concentration of the highly immunogenic 33-mer gliadin peptide was reduced by more than 50-fold within 90 min with no overt signs of toxicity. No human clinical trials of isolated EP-B2 as a supplement have been published; this evidence remains at the animal (preclinical) level.

6.7 Summary of Evidence Strength

Overall, the field of glutenase supplementation remains at an early stage. Clinical studies investigating the effect of glutenases on symptoms and biomarkers in CD patients is unfortunately not as straightforward as it might seem. Not all promising enzymes have been tested in vivo. Previous in vitro studies have demonstrated that some glutenases are efficient in catalyzing the digestion of gluten proteins in acidic conditions, reporting degradation of up to 70–99% of gluten protein load. However, in vitro efficiency does not reliably translate to in vivo clinical outcomes. The use of gluten-degrading enzymes cannot generally be recommended for the treatment of celiac disease or non-celiac gluten or wheat sensitivity.

7. Body Systems and Health Areas

Glutenase activity and research is concentrated on the following body systems and disease areas:

• Gastrointestinal system / small intestine mucosa: The primary target. Celiac disease pathology centers on villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis in the small intestinal mucosa triggered by immunogenic gluten peptides. Glutenases are intended to prevent these peptides from reaching the duodenum and jejunum intact.
• Immune system / T-cell responses: The mode of action of these enzymes is based on studies that have shown that the immunogenicity of gluten can be reduced by breaking down the gluten protein into smaller peptides. ALV003 was shown to reduce peripheral T-cell IFN-γ ELISpot responses in celiac patients, indicating attenuation of antigen-specific immune activation.
• Skin (dermatitis herpetiformis): Two key randomized, double-blind, placebo-controlled studies in patients with dermatitis herpetiformis and celiacs respectively have been conducted. Dermatitis herpetiformis (DH) is a blistering skin manifestation of celiac disease, and caricain supplementation was found to reduce skin lesion size in a clinical challenge study.
• Functional gastrointestinal symptoms in NCGS: Glutenase enzyme mixtures have been studied for symptomatic benefit in non-celiac gluten sensitivity, with one small-scale positive clinical trial.

8. Dosage Forms and Dosages Reported in Studies

Dosages are reported here only as they appear in the published clinical and preclinical literature:

• ALV003 (Latiglutenase) — Phase 1: ALV003 was dosed at escalating dose levels by cohort (100, 300, 900, and 1,800 mg) and gastric samples were aspirated using a nasogastric tube.
• ALV003 (Latiglutenase) — Phase 2: The phase 2 trial context involved an everyday gluten-free diet containing daily up to 2 g gluten, with ALV003 administered daily at the time of gluten ingestion. In the NCT01917630 Phase 2b trial, different doses of ALV003 were evaluated over 12 weeks.
• AN-PEP (Healthy Volunteers Study): In a randomised, double-blind, placebo-controlled, cross-over study with 12 healthy volunteers, a liquid meal containing 4 g gluten with AN-PEP or placebo was administered into the stomach.
• AN-PEP (Gluten-Sensitive Subjects Study): 18 gluten-sensitive subjects consumed a porridge containing 0.5 g gluten together with two tablets either containing a high or low dose of AN-PEP, or placebo. In the stomach, gluten levels were reduced from 176.9 (median, interquartile range 73.5–357.8) to 22.0 (10.6–50.8, p=0.001) in the high dose and to 25.4 μg × min/ml (16.4–43.7, p=0.001) in the low dose.
• Caricain / GluteGuard (CeD study): Each tablet of GluteGuard contained 18,000 U of caricain. Fourteen patients received GluteGuard while all subjects received 1 g of gluten daily for 45 days.
• Caricain (DH study): Patients were challenged with 6 g of gluten daily for 14 days.
• EP-B2 (rat model): The proenzyme form of EP-B2 was orally administered to adult rats with a solid meal containing 1 g of gluten, at a ratio of 1:25 (enzyme:gluten by mass).
• DPP-IV commercial supplements: There is no universal, evidence-based dosing standard for DPP-IV-labeled digestive products. Reputable labels specify activity units rather than milligrams. On the market, hundreds to low-thousands of DPP-IV units per capsule can be found.

9. Safety Considerations and Interactions

9.1 Allergen Content and Undisclosed Ingredients

Among 14 commercially available glutenase products, two did not state the protease contents, and eight failed to specify the name or origin of all proteases. One declared wheat and milk as allergens, two contained herbal products (type not stated), and one contained Carica papaya. The presence of wheat as a declared allergen in one product studied by researchers at Columbia University's Celiac Disease Center is a significant safety concern for individuals with celiac disease.

9.2 Risk of Dietary Non-Adherence

A major safety concern identified by researchers is behavioral rather than biochemical. There are glutenases available marketed as dietary supplements that have not been demonstrated to digest the toxic epitopes of gluten. The potential exists for patients with celiac disease — for whom the gluten-free diet is the only established treatment — to incorrectly believe that over-the-counter glutenase products provide sufficient protection to permit deliberate gluten ingestion. These products have minimal published evidence of efficacy and may actually be hazardous to patients with CD who are taking them.

9.3 In Vivo Stability and Acidic Environment

Structural instability of gluten-degrading enzymes in the digestive tract and autodegradation of enzymes are major challenges for the therapeutic application of these enzymes. Due to the proteinaceous nature of enzymes, they are subject to inactivation and/or digestion in the gastrointestinal tract by gastric acid and under proteolytic conditions. As a consequence, these enzymes may fail to degrade and efficiently inactivate gluten before it reaches the small intestine, the site where gluten induces inflammatory T-cell responses that lead to CeD.

9.4 Limitations of DPP-IV Products

Often, the gluten-degrading capacity of commercially available enzymatic products has not been tested, or alternatively showed to be rather low. The commonly used fungal enzyme DPP-IV, a dipeptidyl peptidase, is not active at a low pH and, hence, not very effective in an acidic gastric environment. DPP-IV, an X-Pro amino-exopeptidase from Aspergillus oryzae, is inactive at stomach pH 3.5, but optimally active at intestinal pH 7.0. DPP-IV was resistant to pepsin and only releases proline-containing dipeptides from the N-terminus. This means it cannot cleave larger internal sequences and leaves immunogenic peptide remnants potentially intact.

9.5 Regulatory Status

Disclaimers on commercially available glutenase products included language stating they have not been evaluated by the US Food and Drug Administration and that products are not intended to diagnose, treat, cure, or prevent any disease. Researchers at Columbia University called for greater FDA oversight of the supplements and encouraged physicians treating those with celiac disease to ask patients if they are taking them, particularly since patients increasingly get medical information from the Internet.

9.6 Caricain-Specific Considerations

In the presence of trypsin/pH 8.0/37°C, caricain is susceptible to destruction. Hence it may be effective only in the gastric digestion of wheat gluten prior to the food bolus reaching the intestine. This means that enteric delivery formulations and the timing of ingestion are critical variables, and that protection beyond the stomach compartment may be incomplete.

9.7 ALV003 Safety Signal

In the phase 1 trial of ALV003 across dose levels from 100 to 1,800 mg, ALV003 has demonstrated safety in clinical studies, with no significant adverse reactions reported, even at doses as high as 1800 mg. However, it should be noted that ALV003 / Latiglutenase is an investigational drug, not a licensed dietary supplement, and its safety profile was evaluated under rigorous clinical trial conditions with biopsy-confirmed monitoring.

9.8 Overall Regulatory and Evidence Caution

The use of gluten-degrading enzymes cannot generally be recommended for the treatment of celiac disease or non-celiac gluten or wheat sensitivity. Nowadays, the commercially available enzymes are marketed as digestive aids. The gap between in vitro efficacy data and confirmed in vivo clinical benefit remains a central limitation of the entire glutenase supplement category.

References

• Krishnareddy S, et al. Commercially available glutenases: a potential hazard in coeliac disease. Therapeutic Advances in Gastroenterology. 2017;10(6):473–481. PMC5424869
• Tack GJ, et al. Gluten Degrading Enzymes for Treatment of Celiac Disease. Nutrients. 2020;12(7):2095. PMC7400306
• Lombardi E, et al. E40, a novel microbial protease efficiently detoxifying gluten proteins, for the dietary management of gluten intolerance. Scientific Reports. 2019;9(1):13147. PMC6739405
• Caminero A, et al. A new microbial gluten-degrading prolyl endopeptidase: Potential application in celiac disease to reduce gluten immunogenic peptides. PLOS One. 2019;14(6):e0218346. PMC6597064
• Lähdeaho ML, et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology. 2014;146(7):1649–1658. PMID: 24583059
• Tye-Din JA, et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Clinical Immunology. 2011;138(2):217–224. PMID: 21948339
• Tye-Din JA, et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clinical Immunology. 2010;134(3):289–295. PMID: 19942485
• König J, et al. Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting. Scientific Reports. 2017;7(1):13100. PMC5638938
• Salden BN, et al. Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers. Alimentary Pharmacology & Therapeutics. 2015;42(3):273–285.
• Mitea C, et al. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut. 2008;57(1):25–32. PMID: 17494108
• Caminero A, Verdu EF. Is an enzyme supplement for celiac disease finally on the cards? Expert Review of Gastroenterology & Hepatology. 2018;12(6):545–547.
• Tanner GJ. Relative Rates of Gluten Digestion by Nine Commercial Dietary Digestive Supplements. Frontiers in Nutrition. 2021;8:784850. PMC8688929
• Skovbjerg H, et al. The Effect of Enzyme Supplementation on Symptoms and Duodenal Histology in Celiac Patients. International Journal of Celiac Disease. 2016;4(2):40–47.
• Ido H, et al. Combination of Gluten-Digesting Enzymes Improved Symptoms of Non-Celiac Gluten Sensitivity: A Randomized Single-blind, Placebo-controlled Crossover Study. Clinical and Translational Gastroenterology. 2018;9(9):181. PMC6143542
• Poddighe D, Marseglia GL. Evolving Therapy for Celiac Disease. Frontiers in Pediatrics. 2019;7:193. PMC6530343
• Tanner GJ, et al. Digestibility of wheat alpha-amylase/trypsin inhibitors using a caricain digestive supplement. Frontiers in Nutrition. 2022;9:977206. PMC9399795
• Gass J, et al. Effect of Barley Endoprotease EP-B2 on Gluten Digestion in the Intact Rat. Journal of Pharmacology and Experimental Therapeutics. 2006;318(3):1178–1186.
• Siegel M, et al. A scaleable manufacturing process for pro-EP-B2, a cysteine protease from barley indicated for celiac sprue. Biotechnology and Bioengineering. 2007;98(2):447–460. PMID: 17385743
• Cristofori F, et al. New therapies in celiac disease. United European Gastroenterology Journal. 2025. PMC11970589
• Siegel M, et al. A Food-Grade Enzyme Preparation with Modest Gluten Detoxification Properties. PLOS One. 2009;4(7):e6313. PMC2708912
• Comino I, et al. Effect of Aspergillus niger prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet. World Journal of Gastroenterology. 2024;30(11):1545.
• Freeman HJ. Emerging drugs for celiac disease. Expert Opinion on Emerging Drugs. 2015;20(1):129–135. PMID: 25494908